Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
Aged
Aged, 80 and over
Alzheimer Disease
/ cerebrospinal fluid
Amyloid beta-Peptides
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Cardiovascular Diseases
/ cerebrospinal fluid
Cognitive Dysfunction
/ cerebrospinal fluid
Diabetes Mellitus
/ epidemiology
Female
Follow-Up Studies
Humans
Hypercholesterolemia
/ epidemiology
Hypertension
/ epidemiology
Male
Middle Aged
Obesity
/ epidemiology
Peptide Fragments
/ cerebrospinal fluid
Risk Factors
Smoking
/ epidemiology
tau Proteins
/ cerebrospinal fluid
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
08 12 2020
08 12 2020
Historique:
received:
30
03
2020
accepted:
22
07
2020
pubmed:
30
9
2020
medline:
16
12
2020
entrez:
29
9
2020
Statut:
ppublish
Résumé
To determine whether vascular risk and Alzheimer disease (AD) biomarkers have independent or synergistic effects on cognitive decline and whether vascular risk is associated with the accumulation of AD pathology as measured by change in biomarkers over time. At baseline, participants (n = 168) were cognitively normal and primarily middle-aged (mean 56.4 years, SD 10.9 years) and had both vascular risk factor status and proximal CSF biomarkers available. Baseline vascular risk was quantified with a composite vascular risk score reflecting the presence or absence of hypertension, hypercholesterolemia, diabetes, current smoking, and obesity. CSF biomarkers of β-amyloid (Aβ) There was no evidence of a synergistic relationship between the vascular risk score and CSF AD biomarkers and cognitive decline. Instead, the vascular risk score (estimate -0.022, 95% confidence interval [CI] -0.043 to -0.002, The results of this observational cohort study suggest that vascular risk and biomarkers of AD pathology, when measured in midlife, act along independent pathways and underscore the importance of accounting for multiple risk factors for identifying cognitively normal individuals at the greatest risk of cognitive decline.
Identifiants
pubmed: 32989109
pii: WNL.0000000000010946
doi: 10.1212/WNL.0000000000010946
pmc: PMC7734925
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
MAPT protein, human
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
tau Proteins
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3093-e3103Subventions
Organisme : NIA NIH HHS
ID : P30 AG066507
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG033655
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005146
Pays : United States
Informations de copyright
© 2020 American Academy of Neurology.
Références
J Neuroimaging. 2007 Apr;17(2):148-55
pubmed: 17441836
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
JAMA Neurol. 2014 Nov;71(11):1379-85
pubmed: 25222039
Neurology. 2012 Sep 25;79(13):1349-55
pubmed: 22972646
Neurology. 2018 Jan 16;90(3):e206-e213
pubmed: 29263220
Neurobiol Aging. 2018 Nov;71:72-80
pubmed: 30099348
Acta Neuropathol. 2017 Aug;134(2):171-186
pubmed: 28488154
J Nucl Med. 2014 May;55(5):759-64
pubmed: 24652830
Alzheimers Dement. 2015 May;11(5):504-510.e1
pubmed: 25043908
Mol Psychiatry. 2016 Jul;21(7):910-5
pubmed: 26324099
Neurobiol Aging. 2016 Jun;42:124-31
pubmed: 27143429
Ann Neurol. 2019 Feb;85(2):272-279
pubmed: 30565287
Acta Neuropathol. 2010 Sep;120(3):287-96
pubmed: 20623294
Neurology. 2020 Mar 3;94(9):e950-e960
pubmed: 31888969
Brain. 2015 Mar;138(Pt 3):761-71
pubmed: 25595145
J Alzheimers Dis. 2010;20(3):699-709
pubmed: 20182020
Neurology. 2015 Sep 29;85(13):1123-30
pubmed: 26333802
JAMA Neurol. 2018 Sep 1;75(9):1124-1131
pubmed: 29799986
J Am Geriatr Soc. 2009 Nov;57(11):1975-81
pubmed: 19793158
BMJ Open. 2018 Nov 25;8(11):e023664
pubmed: 30478117
Neurology. 2013 Nov 12;81(20):1753-8
pubmed: 24132375
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Curr Alzheimer Res. 2014;11(8):773-84
pubmed: 25212916
Neurobiol Aging. 2012 Apr;33(4):827.e11-9
pubmed: 21821316
Ann Neurol. 2008 Aug;64(2):168-76
pubmed: 18496870
Alzheimers Dement. 2019 Sep;15(9):1149-1159
pubmed: 31378575
Lancet Neurol. 2013 Oct;12(10):957-65
pubmed: 24012374
Neurology. 2018 Jan 2;90(1):e73-e81
pubmed: 29196581
Neurobiol Aging. 2000 Jan-Feb;21(1):57-62
pubmed: 10794849
Arch Neurol. 2012 Feb;69(2):246-50
pubmed: 22332192
JAMA Neurol. 2017 Oct 1;74(10):1246-1254
pubmed: 28783817
Nat Neurosci. 2015 Jun;18(6):800-6
pubmed: 26007213
JAMA. 2017 Apr 11;317(14):1443-1450
pubmed: 28399252
Neurobiol Aging. 2015 Sep;36(9):2501-8
pubmed: 26119224
BMJ. 2001 Jun 16;322(7300):1447-51
pubmed: 11408299
Alzheimers Res Ther. 2012 Jan 04;4(1):1
pubmed: 22182734
Neurology. 2010 Sep 28;75(13):1195-202
pubmed: 20739645
Neurology. 2006 Dec 12;67(11):1960-5
pubmed: 17159101
Alzheimers Dement. 2019 Mar;15(3):418-428
pubmed: 30367828
J Alzheimers Dis. 2014;42(4):1295-310
pubmed: 25024338
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
BMC Med. 2014 Nov 11;12:206
pubmed: 25385447
Ann Neurol. 2020 Jan;87(1):52-62
pubmed: 31721283
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Cogn Behav Neurol. 2015 Sep;28(3):144-52
pubmed: 26413742
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Neurology. 2013 Dec 3;81(23):2024-7
pubmed: 24225352
Ann Intern Med. 2014 Dec 2;161(11):785-93
pubmed: 25437406
JAMA Neurol. 2016 Jun 1;73(6):698-705
pubmed: 27064267
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248